If you are comparing glucagon-like peptide-1 doses for weight loss, the first question is not "What dose works best?"
It is "Which product are we talking about?"
Wegovy, Zepbound, Saxenda, diabetes-labeled products, and compounded preparations do not share one dose chart. The active ingredient, route, concentration, escalation schedule, maintenance range, missed-dose rules, and tolerability plan all matter.
After menopause, that dose decision also needs a body-composition plan. Weight loss that ignores protein, resistance training, constipation, hydration, gallbladder symptoms, kidney risk, diabetes medicines, and long-term maintenance can look successful on the scale while creating a weaker plan.
Glucagon-like peptide-1 dosage is product-specific
The dose schedule should start with the label or the clinician's documented plan, not with a social-media chart.
| Product | Label starting dose | Escalation and maintenance shape | What to notice |
|---|---|---|---|
| Wegovy injection (semaglutide) | 0.25 mg once weekly for weeks 1-4 | 0.5 mg weeks 5-8, 1 mg weeks 9-12, 1.7 mg weeks 13-16, then maintenance. Adult weight-reduction maintenance is 1.7 mg or 2.4 mg weekly, with 2.4 mg recommended. [1] | The current label also says some adults who tolerate 2.4 mg for at least 4 weeks may increase to a maximum 7.2 mg weekly when additional weight reduction is clinically indicated. That is not a do-it-yourself step. [1] |
| Wegovy tablet (semaglutide) | 1.5 mg once daily for days 1-30 | 4 mg days 31-60, 9 mg days 61-90, then 25 mg daily from day 91 onward. [1] | Tablets have their own administration rules and should not be converted casually from injection charts. |
| Zepbound (tirzepatide) | 2.5 mg once weekly for 4 weeks | Increase to 5 mg after 4 weeks; then increase in 2.5 mg steps after at least 4 weeks on the current dose. Maintenance for weight reduction is 5 mg, 10 mg, or 15 mg weekly; maximum is 15 mg weekly. [2] | The 2.5 mg dose is for treatment initiation, not maintenance. Tolerability should guide maintenance choice. [2] |
| Saxenda (liraglutide) | 0.6 mg once daily for 1 week | 1.2 mg week 2, 1.8 mg week 3, 2.4 mg week 4, then 3 mg daily from week 5 onward. [3] | Saxenda is a daily injection. The label says to evaluate body-weight change at 16 weeks and discontinue if the patient has not lost at least 4 percent of baseline weight. [3] |
That table is not a prescription. It is a way to see why "glucagon-like peptide-1 dosage" is the wrong level of detail. The exact product and indication come first.
The maintenance dose is not always the fastest dose
Many readers assume that reaching the highest dose is the goal. Labels and real care are more practical than that.
Wegovy labeling says that if patients do not tolerate a dose during escalation, clinicians can consider delaying escalation. It also says that if two or more consecutive injection doses are missed, reinitiation at a lower dose can be considered to reduce gastrointestinal adverse reactions. [1]
Zepbound labeling says to consider treatment response and tolerability when selecting a maintenance dose, and to consider a lower maintenance dose if a patient does not tolerate the current maintenance dose. [2]
The clinical point is simple: a dose that a patient cannot eat, drink, move, or sleep on is not a better dose just because it is higher.
| Dose problem | Why it matters after menopause | Practical clinician question |
|---|---|---|
| Nausea or reflux rises with each increase | It can reduce protein intake and worsen sleep. | Should escalation wait until meals, fluids, and reflux are stable? |
| Constipation worsens | Constipation can overlap with calcium, iron, thyroid medicines, low fluids, and lower activity. | What bowel plan should be in place before the next dose? |
| Appetite suppression is too strong | Very low intake can threaten muscle, bone-supportive nutrition, and hair shedding risk. | Is this dose producing healthful loss or under-eating? |
| Diabetes medicines are involved | Lower intake can change hypoglycemia risk with insulin or insulin secretagogues. | Does the diabetes plan need adjustment before dose escalation? |
| A procedure is planned | Glucagon-like peptide-1 medicines can affect gastric emptying and anesthesia planning. | What should the anesthesia team know, and when? |
Where compounded glucagon-like peptide-1 dosing can help and where it needs caution
Compounding should not be framed as automatically bad. It also should not be framed as automatically equivalent to an FDA-approved pen, tablet, or vial.
FDA's compounding Q&A says compounding can serve an important patient need when an FDA-approved drug is not medically appropriate for a patient, such as when a patient needs a medicine without a certain dye or needs a different dosage form. [5]
In glucagon-like peptide-1 care, that patient-specific logic can matter. A clinician-directed compounded plan may be considered when there is a documented need for individualized titration, a different dosage form, or an ingredient or excipient adjustment. That is personalization, not a moral failure.
The verification standard has to be higher because the product is different. FDA says compounded drugs are not FDA-approved, meaning FDA does not verify their safety, effectiveness, or quality before marketing. FDA has also warned about unapproved glucagon-like peptide-1 products, dosing errors, salt-form concerns, fraudulent labels, and adverse-event reports involving compounded semaglutide and tirzepatide. [4] [5]
| Compounded-plan detail | Why it needs to be written down |
|---|---|
| Patient-specific reason | Personalization should be tied to a clinical reason, such as titration, dosage form, or excipient need. |
| Pharmacy identity | The patient and clinician should know who made the medicine and how problems are reported. |
| Active ingredient | Semaglutide or tirzepatide should not be replaced with an unverified salt form or unlabeled ingredient. |
| Concentration | Vial concentration determines how many milligrams are in a measured volume. |
| Dose unit | Milligrams, milliliters, and syringe units are not interchangeable. |
| Escalation and hold rules | A personalized path still needs clear instructions for nausea, constipation, vomiting, missed doses, and red flags. |
The benefit of compounding is patient-specific flexibility. The responsibility is product-specific precision.
What changes after menopause
Menopause does not create a separate FDA dose schedule. It changes the context around the dose.
Body composition shifts after midlife can make muscle and bone protection more important during weight loss. Constipation may already be present. Reflux, thyroid medicines, antidepressants, blood-pressure medicines, sleep apnea, alcohol, low protein intake, and hot-flash-related sleep disruption can all affect tolerability and follow-up.
A useful dose visit should cover:
- Product name, route, dose, concentration, and last dose date.
- Current nausea, reflux, bowel pattern, hydration, dizziness, and abdominal pain.
- Protein intake, resistance training, strength change, hair shedding, and bone-risk context.
- Diabetes medicines, blood-pressure medicines, thyroid medicine timing, and procedure plans.
- Gallbladder history, pancreatitis history, kidney vulnerability during dehydration, pregnancy possibility, MTC or MEN 2 history, and serious allergy history.
- What dose should be held, delayed, lowered, escalated, or switched.
The right dose is not only about weight-loss speed. It is about whether the plan is sustainable enough to protect function.
How to compare dose schedules without over-reading them
Trial results explain why glucagon-like peptide-1 and related medicines are taken seriously. STEP 1 tested once-weekly semaglutide 2.4 mg in adults with overweight or obesity and found -14.9 percent mean body-weight change at 68 weeks versus -2.4 percent with placebo. [6]
SURMOUNT-1 tested tirzepatide 5 mg, 10 mg, and 15 mg in adults with obesity or overweight and found substantial mean percentage weight reductions at 72 weeks versus placebo. [7]
Those results do not mean every patient should race to the highest dose. They mean a clinician has a real evidence base to weigh against side effects, contraindications, medication interactions, cost, access, and long-term maintenance.
| Reader question | Better framing |
|---|---|
| "What is the strongest dose?" | Which labeled product fits, and what dose can be tolerated safely? |
| "Can I skip ahead?" | What side effects, hydration, glucose medicines, and red flags make skipping unsafe? |
| "Can I stay low?" | Is the lower dose improving appetite or health markers without intolerable symptoms? |
| "Can the dose be personalized?" | What patient-specific need is documented, and how will the product and dose be verified? |
| "What if I plateau?" | Are nutrition, strength training, sleep, adherence, access, and maintenance being reviewed before dose escalation? |
Red flags before the next dose
Call for clinician instructions before taking the next dose if there is repeated vomiting, inability to keep fluids down, faintness, signs of dehydration, severe constipation, severe or persistent abdominal pain, pain moving to the back, fever or jaundice with upper-abdominal pain, blood sugar lows, allergic swelling, new weakness, or a planned procedure with sedation or anesthesia.
This is especially important with vials, compounded products, or any situation where the patient draws up a dose. FDA has received reports of dosing errors with compounded injectable semaglutide, including some requiring hospitalization. [4]
Who this dosing discussion fits
This fits a woman who is comparing prescription weight-loss medication options, already using a glucagon-like peptide-1 or related medication, or considering a compounded plan and trying to understand what dose questions belong in a clinician visit.
It is not a fit for copying a chart into self-treatment, skipping contraindication review, changing syringe units without instructions, or escalating because a lower dose feels "too low." Those situations need product-level clarification before the next dose.
What to ask a clinician
Ask:
- Which product and label category am I using: Wegovy, Zepbound, Saxenda, a diabetes-labeled product, or a compounded preparation?
- What is my exact dose in milligrams, and what volume or device delivers that dose?
- What dose is next, and what symptoms would make us delay, lower, hold, or switch?
- What is the plan for nausea, reflux, constipation, hydration, and protein intake before the next increase?
- How will we protect lean mass, strength, bone, hair, and long-term maintenance?
- Do my diabetes medicines, thyroid medicine, blood-pressure medicines, gallbladder history, kidney history, or procedure plans change the schedule?
- If compounding is used, what patient-specific need does it solve, what ingredient and concentration are listed, and how are dose units checked?
Bottom line
Glucagon-like peptide-1 dosage for weight loss is a product-specific, clinician-led decision. Wegovy, Zepbound, Saxenda, and compounded preparations use different dose logic. After menopause, the strongest plan is not simply the highest dose. It is the dose path that supports weight loss while protecting hydration, bowel function, glucose safety, protein intake, muscle, bone, and long-term maintenance.
Related reading:
- glucagon-like peptide-1 dose escalation after menopause.
- glucagon-like peptide-1 side effects after menopause.
- Compounded Semaglutide After Menopause.
- glucagon-like peptide-1 muscle loss after menopause.
- stopping glucagon-like peptide-1 after menopause.
References
[1] DailyMed. WEGOVY semaglutide injection and tablet prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
[2] DailyMed. ZEPBOUND tirzepatide injection prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
[3] DailyMed. SAXENDA liraglutide injection prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
[4] FDA. FDA's concerns with unapproved glucagon-like peptide-1 drugs used for weight loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
[5] FDA. Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
[6] Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/nejmoa2032183 https://pubmed.ncbi.nlm.nih.gov/33567185/
[7] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/nejmoa2206038 https://pubmed.ncbi.nlm.nih.gov/35658024/